论文部分内容阅读
目的：为临床应用尼莫通和川芎嗪治疗缺血性脑血管病提供充分的理论依据。方法：对实验大鼠于脑缺血前应用尼莫通和川芎嗪进行药物干预，然后采用免疫组化法检测脑缺血 再灌注不同时间内ｃ ｆｏｓ 及ｂｃｌ ２蛋白表达的变化。结果：①与未用药组相比，尼莫通组和川芎嗪组大鼠脑缺血后的梗死体积显著减小，但两用药组之间相比无显著性差异；②尼莫通组和川芎嗪组脑缺血 再灌注时皮质和基底节区ｃ ｆｏｓ的表达明显下降；而ｂｃｌ ２ 的表达明显增高。结论：尼莫通和川芎嗪具有神经保护作用
Objective: To provide sufficient theoretical basis for the clinical application of nimotop and ligustrazine in the treatment of ischemic cerebrovascular disease. Methods: Nimodone and ligustrazine were administered to the experimental rats before cerebral ischemia, and then the expressions of c-fos and bcl-2 proteins were detected by immunohistochemical method at different time points after cerebral ischemia-reperfusion. Results: (1) Compared with the untreated group, the infarct volume in the nimotong and ligustrazine groups decreased significantly after cerebral ischemia, but there was no significant difference between the two groups The expression of c fos in cortex and basal ganglia decreased significantly in ligustrazine group while cerebral ischemia and reperfusion, while the expression of bcl 2 was significantly increased. Conclusion: Nimotop and ligustrazine have neuroprotective effects